Listing 3 - Actual negotiations

Indication:

Non-small cell lung cancer (NSCLC) adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations

Indication:

Metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation in patients who have not received any prior anti-cancer therapy for metastatic disease

Indication:

Corticosteroid-Responsive Dermatoses and The Topical Treatment of Plaque Psoriasis

Indication:

Diabetes Mellitus, Type 1 & 2

Indication:

Vision loss, inherited retinal dystrophy

Indication:

Breast cancer, locally advanced unresectable or metastatic, HER2-positive, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination (in combination with trastuzumab and capecitabine)

Indication:

Mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.

Indication:

Cardiomyopathy due to transthyretin-mediated amyloidosis

Indication:

Acne Vulgaris

Indication:

Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, monotherapy for first-line treatment of adult patients